摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(4-ethylphenyl)-azetidine hydrochloride | 1430841-43-2

中文名称
——
中文别名
——
英文名称
3-(4-ethylphenyl)-azetidine hydrochloride
英文别名
3-(4-Ethylphenyl)azetidine hydrochloride;3-(4-ethylphenyl)azetidine;hydrochloride
3-(4-ethylphenyl)-azetidine hydrochloride化学式
CAS
1430841-43-2
化学式
C11H15N*ClH
mdl
——
分子量
197.708
InChiKey
WFVKEEUEBMSATG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.36
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.45
  • 拓扑面积:
    12
  • 氢给体数:
    2
  • 氢受体数:
    1

文献信息

  • [EN] PDE9I WITH IMIDAZO PYRAZINONE BACKBONE<br/>[FR] PDE9I AYANT UN SQUELETTE IMIDAZO PYRAZINONE
    申请人:LUNDBECK & CO AS H
    公开号:WO2013053690A1
    公开(公告)日:2013-04-18
    This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I). The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).
    该发明涉及一类PDE9酶抑制剂化合物。该发明提供了一种药物组合物,包括该发明化合物的治疗有效量和药用载体。本发明还提供了制备式(I)化合物的方法。本发明还提供了一种治疗患有神经退行性疾病的受试者的方法,包括向受试者投与式(I)化合物的治疗有效量。本发明还提供了一种治疗患有精神疾病的受试者的方法,包括向受试者投与式(I)化合物的治疗有效量。
  • PDE9i with imidazo pyrazinone backbone
    申请人:H. LUNDBECK A/S
    公开号:US20150274736A1
    公开(公告)日:2015-10-01
    This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I). The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).
    本发明涉及一种PDE9酶抑制剂化合物。该发明提供了一种药物组合物,包括本发明化合物的治疗有效量和药学可接受的载体。本发明还提供了制备式(I)化合物的方法。本发明还提供了一种治疗神经退行性疾病的方法,包括向患者投与式(I)化合物的治疗有效量。本发明还提供了一种治疗精神障碍的方法,包括向患者投与式(I)化合物的治疗有效量。
  • PDE9 INHIBITOR WITH IMIDAZO PYRAZINONE BACKBONE
    申请人:H. Lundbeck A/S
    公开号:EP3121178A1
    公开(公告)日:2017-01-25
    This invention is directed to 6-[4-METHYL-1-(PYRlMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL]-3-TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-A]PYRAZIN-8-ONE and pharmaceutically acceptable acid addition salts thereof, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of invention. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of the invention. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).
    本发明涉及6-[4-甲基-1-(PYRlMIDIN-2-YLMEYTHL)PYRROLIDIN-3-YL]-3-四氢吡喃-4-YL-7H-IMIDAZO[1,5-A]PYRAZIN-8-ONE及其药学上可接受的酸加成盐,它们是PDE9酶抑制剂。本发明提供了一种药物组合物,其包含治疗有效量的本发明化合物和药学上可接受的载体。本发明还提供了制备本发明化合物的工艺。本发明进一步提供了一种治疗患有神经退行性疾病的受试者的方法,该方法包括向受试者施用治疗有效量的本发明化合物。本发明进一步提供了一种治疗精神疾病患者的方法,包括对该患者施用治疗有效量的式(I)化合物。
  • PDE9I WITH IMIDAZO PYRAZINONE BACKBONE
    申请人:H. Lundbeck A/S
    公开号:EP2906562A1
    公开(公告)日:2015-08-19
  • 6-[4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL]-3-TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-A]PYRAZIN-8-ONE AS PDE9 INHIBITOR
    申请人:H. Lundbeck A/S
    公开号:EP3121178B1
    公开(公告)日:2018-09-19
查看更多

同类化合物

顺-2,4-二羟甲基-1-叔丁氧羰基氮杂环丁烷 盐酸2-环丙基吖丁啶 甲基5-甲基-2-氮杂双环[2.2.0]己-5-烯-2-羧酸酯 甲基3-(氮杂环丁烷-3-基)苯甲酸酯盐酸盐 氮杂环丁烷-3-醇 氮杂环丁烷-3-酮盐酸盐 氮杂环丁烷-3-酮; 3-氧代氮杂环丁烷 氮杂环丁烷-3-腈 氮杂环丁烷-3-甲酸甲酯盐酸盐 氮杂环丁烷-1-羧酰胺 氮杂啶-3-乙酸 氮杂啶-2-甲醇 氮杂丁烷-3-羧酸乙酯盐酸盐 氮杂丁烷-3-羧酸.盐酸盐 氮杂丁烷-1,3,3-三羧酸1-叔丁酯3-乙酯 杂氮环丁烷 替比培南杂质 哌醋甲酯杂质 吖丁啶,3-(3,4-二氯苯基)-1-甲基- 叔丁基6-羟基-2-氮杂螺[3.4]辛烷-2-羧酸酯 叔丁基6-氧代-5-氧杂-2,7-二氮杂螺[3.4]辛烷-2-羧酸盐 叔丁基 2,7-二氮杂螺[3.5]壬烷-2-甲酸酯 盐酸盐 叔-丁基8-羟基-6-硫杂-2-氮杂螺[3.4]辛烷-2-羧酸6,6-二氧化物 叔-丁基8-羟基-5-硫杂-2-氮杂螺[3.4]辛烷-2-羧酸5,5-二氧化物 叔-丁基8-氧杂-5-硫杂-2-氮杂螺[3.4]辛烷-2-羧酸5,5-二氧化物 叔-丁基5-氨基-2-氮杂螺[3.3]庚烷-2-甲酸基酯 叔-丁基5-(羟甲基)-7-氧亚基-2,6-二氮杂螺[3.4]辛烷-2-甲酸基酯 叔-丁基3-羟基-1-氧杂-6-氮杂螺[3.3]庚烷-6-羧酸酯 叔-丁基3-氨基-3-甲基-吖丁啶-1-羧酸酯 叔-丁基3-氧代-1-氧杂-6-氮杂螺[3.3]庚烷-6-羧酸酯 叔-丁基3-叔-丁基亚磺酰亚氨基吖丁啶-1-羧酸酯 叔-丁基3-[甲氧基(甲基)氨基甲酰]吖丁啶-1-羧酸酯 叔-丁基3-(异丙基氨基)吖丁啶-1-甲酸基酯 叔-丁基3-(二氟甲基)-3-羟基吖丁啶-1-甲酸基酯 叔-丁基1,6-二氮杂螺[3.3]庚烷-6-甲酸基酯盐酸 叔-丁基-8-羟基-5-氧杂-2-氮杂螺[[3.4]辛烷-2-羧酸盐 双(2,2,2-三氟乙酸) 二-1-氮杂环丁基甲酮 乙基3-亚甲基-1-吖丁啶羧酸酯 乙基2-氮杂双环[2.2.0]己-5-烯-2-羧酸酯 乙基1-叔丁氧羰基-3-氰基吖丁啶-3-羧酸酯 Sch58053苄基醚 N-甲基-3-氮杂环丁胺 N-甲基-1-甲基氮杂环丁-3-胺 N-甲基-(1-甲基氮杂环丁-3-基)甲胺 N-异丙基氮杂啶-3-胺双盐酸盐 N-boc-3-(4-氨基苯基)氮杂丁烷 N-Boc-氮杂环丁烷 N-Boc-3-羟基氮杂环丁烷 N-Boc-3-氮杂环丁烷乙酸